Tau Antibody Therapy in Neurodegenerative Diseases

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

April 12, 2021

Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis.

Brain : a Journal of Neurology
Sergio Muñiz-CastrilloJérôme Honnorat
March 26, 2021
Open Access

Early alterations of neurovascular unit in the retina in mouse models of tauopathy.

Acta Neuropathologica Communications
Fan XiaWenbo Zhang
March 24, 2021
Preprint
Open Access

Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment

BioRxiv : the Preprint Server for Biology
C. DanisIsabelle Landrieu
March 16, 2021
Open Access

Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology.

Frontiers in Aging Neuroscience
Allal BoutajangoutThomas Wisniewski
March 14, 2021
Open Access

Maternal antibodies facilitate Amyloid-β clearance by activating Fc-receptor-Syk-mediated phagocytosis.

Communications Biology
Tomer IllouzEitan Okun
March 14, 2021
Review

Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases.

Journal of Molecular Neuroscience : MN
Mohammadmahdi SabahiNima Rezaei
March 4, 2021
Open Access

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.

Alzheimer's Research & Therapy
Julia RemnestålAnna Månberg
February 21, 2021
Clinical Trial
Open Access

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Lancet Neurology
Günter U HöglingerArise Investigators
February 14, 2021
Open Access

Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.

Journal of Alzheimer's Disease : JAD
W. H. QuintThomas Vogels
February 1, 2021
Preprint
Open Access

Caspase-6-cleaved tau is relevant in Alzheimer's disease but not in 4-repeat tauopathies: diagnostic and therapeutic implications

MedRxiv : the Preprint Server for Health Sciences
P. TheofilasLea T. Grinberg
January 9, 2021
Preprint
Open Access

Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC-induced neurons with the V337M MAPT mutation

BioRxiv : the Preprint Server for Biology
P. TheofilasLea Tenenholz Grinberg
December 24, 2020
Review

Future Imaging in Dementia.

Seminars in Nuclear Medicine
David J Brooks
December 22, 2020
Review
Open Access

New Insights Into Drug Discovery Targeting Tau Protein

Frontiers in Molecular Neuroscience
Yoshiyuki Soeda, Akihiko Takashima
December 20, 2020
Open Access

C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease

Molecular Psychiatry
Yiyuan XiaXiao-Chuan Wang

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved
/feed-previews/tau-antibody-therapy-in-neurodegenerative/d55e613b-55f6-4469-92e8-bd3a5ea2c43f